In the past week, SNTI stock has gone down by -9.61%, with a monthly decline of -21.60% and a quarterly plunge of -29.83%. The volatility ratio for the week is 8.01%, and the volatility levels for the last 30 days are 6.89% for Senti Biosciences Inc The simple moving average for the last 20 days is -17.88% for SNTI stock, with a simple moving average of -25.19% for the last 200 days.
Is It Worth Investing in Senti Biosciences Inc (NASDAQ: SNTI) Right Now?
Moreover, the 36-month beta value for SNTI is 2.24. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SNTI is 7.97M and currently, short sellers hold a 1.99% of that float. On June 18, 2025, SNTI’s average trading volume was 113.29K shares.
SNTI) stock’s latest price update
Senti Biosciences Inc (NASDAQ: SNTI) has seen a decline in its stock price by -8.63 in relation to its previous close of 2.78. However, the company has experienced a -9.61% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-18 that Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
Analysts’ Opinion of SNTI
Many brokerage firms have already submitted their reports for SNTI stocks, with Laidlaw repeating the rating for SNTI by listing it as a “Buy.” The predicted price for SNTI in the upcoming period, according to Laidlaw is $5 based on the research report published on June 06, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see SNTI reach a price target of $7.50. The rating they have provided for SNTI stocks is “Equal-Weight” according to the report published on October 07th, 2022.
SNTI Trading at -23.79% from the 50-Day Moving Average
After a stumble in the market that brought SNTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.01% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SNTI starting from Lu Timothy K, who sale 3,922 shares at the price of $4.07 back on Feb 04 ’25. After this action, Lu Timothy K now owns 82,627 shares of Senti Biosciences Inc, valued at $15,963 using the latest closing price.
Lu Timothy K, the CEO of Senti Biosciences Inc, sale 545 shares at $4.36 during a trade that took place back on Feb 06 ’25, which means that Lu Timothy K is holding 82,082 shares at $2,376 based on the most recent closing price.
Stock Fundamentals for SNTI
Current profitability levels for the company are sitting at:
- -10.44 for the present operating margin
- 0.25 for the gross margin
The net margin for Senti Biosciences Inc stands at -9.36. The total capital return value is set at -0.85. Equity return is now at value -116.63, with -59.25 for asset returns.
Based on Senti Biosciences Inc (SNTI), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at -1.35.
Currently, EBITDA for the company is -46.94 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 11.01. The receivables turnover for the company is 46.11for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.22.
Conclusion
To wrap up, the performance of Senti Biosciences Inc (SNTI) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
